"Kawartha Cardiology’s mission is to provide comprehensive, integrated services focused on the diagnosis, management, treatment and education of cardiovascular health and rehabilitation."

During the past decade, Kawartha Cardiology Clinical Trials conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 9 clinical trials were completed, i.e. on average, 69.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kawartha Cardiology Clinical Trials" #1 sponsor was "Pfizer" with 5 trials, followed by "Boehringer Ingelheim" with 3 trials sponsored, "Bayer" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Brigham and Women's Hospital" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kawartha Cardiology Clinical Trials" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Kawartha Cardiology Clinical Trials" are "Cardiovascular Disease" (4 trials), "Heart Failure" (3 trials), "Atrial Fibrillation" (2 trials), "Hyperlipidemia" (2 trials) and "Acute Myocardial Infarction" (1 trials). Many other conditions were trialed in "Kawartha Cardiology Clinical Trials" in a lesser frequency.

Most popular intervention types in "Kawartha Cardiology Clinical Trials" are "Drug" (15 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Empagliflozin" (2 trials), "bococizumab (PF-04950615)" (2 trials), "ARRY-371797 (PF-07265803)" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kawartha Cardiology Clinical Trials" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Kawartha Cardiology Clinical Trials". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 7 completed trials in Kawartha Cardiology Clinical Trials, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Kawartha Cardiology Clinical Trials, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".